SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy
Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease
Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression
Abraxane and Gemcitabine Improves Overall Survival
Study Uncovers New Mechanism In Class of Chemotherapy Drugs
Adjuvant Radiation Treatment Shows Improved Survival In Elderly, Early-Stage Patients
Genetic Test Identifies Patients With High Risk of Mortality
Memantine Can Delay Onset Of Cognitive Function Decline
Doxepin Rinse Reduces Pain In Radiation Therapy Patients
Zaltrap Receives Positive Opinion For European Market From CHMP
NCI-Approved CTEP Trials For the Month of November
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
